Collegium Pharmaceutical, Inc. (NASDAQ:COLL)‘s stock had its “buy” rating restated by Needham & Company LLC in a research note issued on Friday. They currently have a $25.00 price target on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price target suggests a potential upside of 112.04% from the stock’s previous close.
Several other research firms have also recently commented on COLL. Zacks Investment Research cut Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Piper Jaffray Companies set a $14.00 target price on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, July 25th. ValuEngine upgraded Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Jefferies Group LLC restated a “buy” rating and issued a $15.00 target price on shares of Collegium Pharmaceutical in a research note on Friday. Finally, BidaskClub cut Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Collegium Pharmaceutical has a consensus rating of “Hold” and an average price target of $20.00.
Shares of Collegium Pharmaceutical (NASDAQ COLL) opened at 11.79 on Friday. Collegium Pharmaceutical has a 52-week low of $9.27 and a 52-week high of $18.67. The stock’s market capitalization is $348.58 million. The stock has a 50 day moving average of $10.53 and a 200-day moving average of $10.53.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.09. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $4.07 million. On average, equities research analysts predict that Collegium Pharmaceutical will post ($3.00) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://transcriptdaily.com/2017/10/08/collegium-pharmaceutical-inc-coll-rating-reiterated-by-needham-company-llc.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd bought a new stake in Collegium Pharmaceutical in the 1st quarter valued at approximately $238,000. Vanguard Group Inc. lifted its stake in Collegium Pharmaceutical by 7.8% in the 1st quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock valued at $8,113,000 after acquiring an additional 58,398 shares in the last quarter. Pier Capital LLC lifted its stake in Collegium Pharmaceutical by 8.1% in the 2nd quarter. Pier Capital LLC now owns 395,658 shares of the specialty pharmaceutical company’s stock valued at $4,950,000 after acquiring an additional 29,594 shares in the last quarter. Morgan Stanley lifted its stake in Collegium Pharmaceutical by 684.8% in the 1st quarter. Morgan Stanley now owns 885,268 shares of the specialty pharmaceutical company’s stock valued at $8,906,000 after acquiring an additional 772,464 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in Collegium Pharmaceutical by 42.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 640,189 shares of the specialty pharmaceutical company’s stock valued at $6,440,000 after acquiring an additional 191,062 shares in the last quarter. Hedge funds and other institutional investors own 83.04% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.